immunofluorescence reagents
Biotime's SARS-CoV-2 Antigen Rapid Qualitative Test has received approval from the China's National Medical Products Administration (NMPA) May 23, 2022

May 20, 2022, Biotime announced that its SARS-CoV-2 Antigen Rapid Qualitative Test has received approval from the China's National Medical Products Administration (NMPA). The details are as follows:

Biotime's SARS-CoV-2 Antigen Rapid Qualitative Test has received NMPA approval


The SARS-CoV-2 Antigen Rapid Qualitative Test has also obtained CE mark for self-testing, which is another effective tool for the company to actively support global anti-epidemic. It can be operated by individuals who collect the front nasal swab sample by themselves, and the result can be quickly delivered in 20-30 minutes.


Since the outbreak of COVID-19, Biotime as a global innovation-driven healthcare company has fully integrated its business and global resources with timely response and actively undertaking the social responsibilities in combating COVID-19 pandemic control and minimizing its impact. Biotime has developed a growing number of diagnostic solutions that help to diagnose and detect the infection, and we will continue to play our role and increase production to support availability of tests globally.


Leave A Message

Leave A Message

    Please provide us with the information below, and we'll contact you as soon as possible.

Home

products

about

contact